Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Strong Launches Will Help BMS Win The LOE Battle In 2023 And Beyond

Three New Drugs Reached US Market In 2022

Executive Summary

Bristol Myers Squibb brought the last of nine new drugs to market last year – all needed to help it overcome three big losses of exclusivity this decade – so the focus this year is commercial execution. 

You may also be interested in...



Future BMS CEO Boerner Pleas For Patience As New Products Build Momentum

Christopher Boerner, who will become CEO on 1 November, reported Q1 progress for new drugs Sotyktu, Camzyos and Opdualag, noting that greater growth for these early launches is still to come.

Bristol’s Boerner To Succeed CEO Caforio With Launch Execution In The Spotlight

Giovanni Caforio will step down as CEO of Bristol Myer Squibb effective 1 November, with chief commercialization officer Boerner primed to succeed him.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: Amgen launches first US biosimilar to Humira; strong launches set to help BMS as it faces losses of exclusivity; Eisai preaches patience on Leqembi for Alzheimer’s; 10 clinical trials to watch for this year; and Scrip Asks what 2023 holds in store for biopharma technological advances.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel